Stock comparison
JOHNSON & JOHNSON is 31.2x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($655.15 B vs $20.99 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
JNJ is larger
JOHNSON & JOHNSON is 31.2x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($655.15 B vs $20.99 B).
Market value leader
JNJ
JOHNSON & JOHNSON is 31.2x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($655.15 B vs $20.99 B).
Revenue leader
JNJ
ALNY: $3.71B vs JNJ: $94.19B.
Profit leader
JNJ
ALNY: $313.75M vs JNJ: $26.80B.
Margin leader
JNJ
ALNY: 8.4% vs JNJ: 28.5% net margin.
| Metric | ALNY | JNJ |
|---|---|---|
| Market cap | $20.99 B | $655.15 B |
| US-listed rank | #600 | #17 |
| Revenue (latest FY) | $3.71B | $94.19B |
| Net income (latest FY) | $313.75M | $26.80B |
| Net margin | 8.4% | 28.5% |
| P/E (trailing FY) | 66.9x | 24.4x |
| SEC filings | 1,651 | 1,004 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
JOHNSON & JOHNSON is 31.2x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($655.15 B vs $20.99 B).
In their latest fiscal years, ALNYLAM PHARMACEUTICALS, INC. reported $3.71B in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: ALNYLAM PHARMACEUTICALS, INC. and JOHNSON & JOHNSON, or browse the full rankings.